
Gene therapy boon
French biotech company Eyevensys has secured US$12m in funding to accelerate its programmes using a non-viral gene therapy ocular drug-delivery platform.
4295 articles

French biotech company Eyevensys has secured US$12m in funding to accelerate its programmes using a non-viral gene therapy ocular drug-delivery platform.

A US study has suggested children and adolescents with type 1 diabetes using insulin pumps may have a lower likelihood of developing diabetic retinopathy (DR).

De Rigo Vision’s Nina Ricci 2021 collection is contemporary and elegant, including iconic optical and sunglass styles clearly representing the brand’s Gallic DNA. Optical model VNR290’s bold, geometric acetate temple gives the style a modern flair, while the thin long temple tips confer lightness to

Following a two-year study, CooperVision’s SightGlass vision business reported that 85% of children wearing its Diffusion Optics Technology (DOT) lenses, designed to slow myopia, had <1.0D myopia progression.

Bausch+Lomb reported that its LuxSmart acrylic intraocular lenses have treated 5,000 cataract patients since its 2020 European launch, with significant improvements for distance and intermediate

Phoenix Eyewear has introduced sustainable eyewear brand Botaniq to our shores.

The Blackfin One 2021-22 optical titanium styles feature strong, unique designs and colour pairings typical of the brand’s DNA. The large round rims of Simos and generous square shape of Paros express a more contemporary spirit, with the thin titanium frames enhanced by architectural cuts on the len

A high-powered international review has criticised unqualified lens suppliers’ inappropriate substitution of soft contact lens (CL) types for ones prescribed by eyecare practitioners.

Facebook’s Ray-Ban Stories smartglasses, which can record photos and video with a voice command, are facing criticism for potential privacy violations.

The long-standing New Zealand Optical Wholesalers Association (NZOWA) has told members it intends to ‘rest’ for five years, to allow them to consider its longer-term future.

Preliminary results from two studies of gene therapies for achromatopsia have shown them to be safe while improving some patients’ photosensitivity and two-colour dark light-adapted perimetry.

Based in Australia, Sasha Sergejew and Matt Murray are CR Surfacing Laboratories’ new business development managers for New Zealand, looking after the South and North Island, respectively. The new appointments follow the departure of business development manager Tertius Van Vuuren, who is pursuing a